Analysts See $-0.54 EPS for Aeglea BioTherapeutics, Inc. (AGLE); Profile of 5 Analysts Covering Otonomy, Inc. (OTIC)

April 30, 2018 - By Dolores Ford

Otonomy, Inc. (NASDAQ:OTIC) Logo

Among 7 analysts covering Otonomy (NASDAQ:OTIC), 5 have Buy rating, 2 Sell and 0 Hold. Therefore 71% are positive. Otonomy had 16 analyst reports since August 10, 2015 according to SRatingsIntel. JP Morgan initiated the shares of OTIC in report on Thursday, August 13 with “Hold” rating. Piper Jaffray initiated the stock with “Buy” rating in Friday, June 2 report. On Thursday, May 26 the stock rating was initiated by WallachBeth Capital with “Buy”. The firm earned “Hold” rating on Wednesday, August 30 by J.P. Morgan. Piper Jaffray maintained the shares of OTIC in report on Thursday, November 9 with “Hold” rating. The firm earned “Overweight” rating on Tuesday, August 15 by JP Morgan. The firm has “Buy” rating by SunTrust given on Thursday, August 31. The stock of Otonomy, Inc. (NASDAQ:OTIC) has “Outperform” rating given on Monday, August 10 by Bernstein. J.P. Morgan upgraded the stock to “Buy” rating in Tuesday, August 15 report. The company was downgraded on Wednesday, August 30 by Piper Jaffray. See Otonomy, Inc. (NASDAQ:OTIC) latest ratings:

19/03/2018 Broker: J.P. Morgan Rating: Sell Downgrade
19/03/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
12/03/2018 Broker: Piper Jaffray Rating: Buy Upgrade
10/11/2017 Broker: SunTrust Rating: Buy New Target: $15.0 Maintain
09/11/2017 Broker: Piper Jaffray Rating: Hold New Target: $8.0 Maintain

Analysts expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to report $-0.54 EPS on May, 8.They anticipate $0.07 EPS change or 14.89% from last quarter’s $-0.47 EPS. After having $-0.38 EPS previously, Aeglea BioTherapeutics, Inc.’s analysts see 42.11% EPS growth. The stock increased 10.50% or $0.84 during the last trading session, reaching $8.84. About 610,599 shares traded or 283.98% up from the average. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) has risen 26.34% since April 30, 2017 and is uptrending. It has outperformed by 14.79% the S&P500.

Among 4 analysts covering Aeglea BioTherapeutics (NASDAQ:AGLE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeglea BioTherapeutics had 4 analyst reports since May 2, 2016 according to SRatingsIntel. The rating was initiated by Wells Fargo with “Outperform” on Monday, May 2. BMO Capital Markets initiated it with “Outperform” rating and $19 target in Monday, May 2 report. UBS initiated the stock with “Buy” rating in Monday, May 2 report. The firm has “Buy” rating given on Monday, May 9 by Needham.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company has market cap of $187.15 million. The Company’s human enzymes are designed to degrade specific amino acids in the blood. It currently has negative earnings. The company's lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies.

The stock increased 2.56% or $0.1 during the last trading session, reaching $4. About 155,933 shares traded. Otonomy, Inc. (NASDAQ:OTIC) has declined 68.11% since April 30, 2017 and is downtrending. It has underperformed by 79.66% the S&P500.

Otonomy, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the United States. The company has market cap of $122.31 million. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It currently has negative earnings. OTIPRIO has also completed a Phase III clinical trial for treating swimmerÂ’s ear and a Phase II clinical trial for treating acute otitis media with tubes.

Investors sentiment decreased to 0.88 in Q4 2017. Its down 0.05, from 0.93 in 2017Q3. It dived, as 20 investors sold Otonomy, Inc. shares while 22 reduced holdings. 22 funds opened positions while 15 raised stakes. 20.13 million shares or 13.85% more from 17.68 million shares in 2017Q3 were reported. The California-based California State Teachers Retirement has invested 0% in Otonomy, Inc. (NASDAQ:OTIC). 51,323 were reported by Parametric Port Associates Ltd Liability Corp. Assetmark Inc owns 0% invested in Otonomy, Inc. (NASDAQ:OTIC) for 73 shares. Tpg Gru Holdg (Sbs) Advsrs reported 2.16 million shares. Highland Capital Management Limited Partnership holds 0.01% or 40,000 shares. The New York-based Millennium Management Limited Liability Company has invested 0% in Otonomy, Inc. (NASDAQ:OTIC). Alliancebernstein Lp, New York-based fund reported 30,300 shares. Mufg Americas Corp has 301 shares for 0% of their portfolio. Geode Management Limited Liability Corp stated it has 0% of its portfolio in Otonomy, Inc. (NASDAQ:OTIC). Barclays Public Limited Liability Corporation has 0% invested in Otonomy, Inc. (NASDAQ:OTIC) for 145,904 shares. Connor Clark And Lunn Investment Mngmt Ltd invested in 0% or 11,969 shares. Morgan Stanley accumulated 0% or 59,328 shares. Drw Lc holds 0.01% in Otonomy, Inc. (NASDAQ:OTIC) or 15,000 shares. Bnp Paribas Arbitrage Sa owns 8,479 shares or 0% of their US portfolio. Reilly Fincl Advsr Lc has 700 shares.

Otonomy, Inc. (NASDAQ:OTIC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>